Results 131 to 140 of about 5,125,209 (406)

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Nature, 2021
Pengfei Wang, M. Nair, Lihong Liu, S. Iketani, Yang Luo, Yicheng Guo, Maple Wang, Jian Yu, Baoshan Zhang, P. Kwong, B. Graham, J. Mascola, Jennifer Y. Chang, M. Yin, M. Sobieszczyk, C. Kyratsous, L. Shapiro, Zizhang Sheng, Yaoxing Huang, D. Ho   +19 more
semanticscholar   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

Lipid Metabolic Pathways Confer the Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Tumor

Frontiers in Immunology, 2019
Myeloid-derived suppressor cells (MDSCs) play crucial roles in tumorigenesis and their inhibition is critical for successful cancer immunotherapy.
Dehong Yan, Adeleye O. Adeshakin, Adeleye O. Adeshakin, Meichen Xu, Meichen Xu, Lukman O. Afolabi, Lukman O. Afolabi, Guizhong Zhang, Youhai H. Chen, Xiaochun Wan, Xiaochun Wan   +10 more
doaj   +1 more source

Tonic signaling of the B‐cell antigen‐specific receptor is a common functional hallmark in chronic lymphocytic leukemia cell phosphoproteomes at early disease stages

Molecular Oncology, EarlyView.
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez, Pablo Juanes‐Velasco, Marina L. García‐Vaquero, Conrad Droste, Alicia Landeira‐Viñuela, Miguel Alcoceba, Helena Fidalgo‐Gómez, Sara Misiego‐Herrero, Almudena Navarro‐Bailón, Mónica Baile, José M. Bastida, Jose Manuel Sanchez‐Santos, Rafael Góngora, Julia Almeida, Marcos Gonzalez‐Diaz, Alberto Orfao, Javier De Las Rivas, Manuel Fuentes   +17 more
wiley   +1 more source

Anti-influenza antibody level after vaccination in north of Iran [PDF]

, 2009
Objective:Influenza is a highly transmitted disease and about 10% of the world's population is affected by this disease annually. The aim of this research was to study the variation of serum antibody levels among subjects who had already been vaccinated ...
Abbasi, A., Mansourian, A.R., Moradi, A., Rajaei, S.   +3 more
core  

Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry

Journal of Virology, 2019
Antibody-dependent enhancement (ADE) of viral entry has been observed for many viruses. It was shown that antibodies target one serotype of viruses but only subneutralize another, leading to ADE of the latter viruses.
Yushun Wan, J. Shang, Shihui Sun, Wanbo Tai, J. Chen, Q. Geng, Lei He, Yuehong Chen, Jianming Wu, Zhènglì Shí, Yusen Zhou, L. Du, Fang Li   +12 more
semanticscholar   +1 more source

Antibody and Antibody Mimetic Immunotherapeutics [PDF]

Future Medicinal Chemistry, 2017
Brian R. McNaughton, Angeline N. Ta
openaire   +2 more sources

Monoclonal Antibodies

Dermatologic Clinics, 2015
Use of monoclonal antibodies (mAbs) has revolutionized cancer therapy. Approaches targeting specific cellular targets on the malignant cells and in tumor microenvironment have been proved to be successful in hematologic malignancies, including cutaneous lymphomas.
openaire   +2 more sources

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source